TWST Falls 6.7% After Pricing Upsized $300M Stock Sale

Twist Bioscience Corporation (Nasdaq: TWST) announced an upsized public stock offering on Aug 4, 2026, and the shares fell 6.7% the same day.

What Twist Bioscience announced

Twist said it priced an upsized underwritten public offering of 3,125,000 shares of common stock at $96.00 per share. All of the shares in the offering are being sold by the company, meaning Twist is issuing new stock to raise cash. Gross proceeds are expected to be $300.0 million before underwriting discounts, commissions, and other offering expenses. Twist also granted underwriters a 30-day option to buy up to an additional 468,750 shares at the public offering price (less underwriting discounts and commissions). The company said it expects the offering to close on August 6, 2026, subject to customary closing conditions.

What it means for Twist Bioscience

This is a straightforward capital raise: Twist is bringing in new money by selling more shares to the public. The company said it intends to use the net proceeds, together with existing cash, cash equivalents, and marketable securities, to fund research and development investments, expand manufacturing capacity, broaden product offerings, and support working capital and other general corporate purposes. In plain English, Twist is signaling it wants more firepower to invest in its pipeline and scale operations. At the same time, issuing new shares can dilute existing shareholders, which is often why the market focuses on the offering size and pricing.

How the stock reacted

TWST sold off quickly after the announcement and stayed lower through the close.

Window	Move
5 min	-5.6%
10 min	-4.9%
30 min	-5.1%
1 hour	-6.7%
end of day	-6.7%

On a market-adjusted basis, TWST underperformed the SPY by -8.1% on Aug 4, 2026.